IAM
BCTXL

Iridian Asset Management’s BriaCell Therapeutics Warrant BCTXL Stock Holding History

Iridian Asset Management’s Portfolio BCTXL Stock Details BCTXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57.9K Hold
65,000
– – 0.02% 41
2026
Q1 		$67K Buy
+65,000
New +$68.8K 0.03% 42

Other funds holding BCTXL

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
MA
MYDA Advisors Woodmere, New York $672M AUM 71.14% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Iridian Asset Management's BCTXL Position: Q2 2026 in Review

Iridian Asset Management held its BriaCell Therapeutics Warrant (BCTXL) position steady in Q2 2026 at 65,000 shares worth $57.9K. The position accounts for 0.02% of the portfolio, ranked #41.

Iridian Asset Management first reported a position in BCTXL in Q1 2026 and has held it in 2 quarters since. The position peaked at $67K in Q1 2026. 10 funds tracked by Wall St. Rank hold BCTXL as of Q2 2026.

  • Iridian Asset Management held 65,000 shares of BriaCell Therapeutics Warrant worth $57.9K as of Q2 2026.
  • Iridian Asset Management left its BriaCell Therapeutics Warrant share count unchanged in Q2 2026.
  • BriaCell Therapeutics Warrant made up 0.02% of Iridian Asset Management's portfolio in Q2 2026, its #41 holding.
  • Iridian Asset Management first reported a position in BriaCell Therapeutics Warrant in Q1 2026 and has held it in 2 quarters since.
  • Iridian Asset Management's BriaCell Therapeutics Warrant position peaked at $67K in Q1 2026.
  • 10 funds tracked by Wall St. Rank held BriaCell Therapeutics Warrant as of Q2 2026.

Based on Iridian Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.